{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-22-000033","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.944178+00:00","generated_at":"2026-06-27T00:09:06.841220+00:00","sec_items":["1.01","2.02","2.03","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xeris closes $150M Hayfin debt facility, reports FY2021 product revenue $79M (+56%) and guides FY2022 $105M-$120M","bullets":["Xeris drew $100M from new $150M Hayfin term loan (9%+SOFR, warrants at $2.28, 5-yr maturity); repaid $43.5M Oxford/SVB debt.","FY2021 net product revenue $79M (pro forma), up 56% YoY; net loss $122.7M ($1.55/share) vs $91.1M ($2.14/share) in 2020.","FY2022 revenue guidance $105M-$120M; year-end cash $90M-$110M; cash flow breakeven targeted by end of 2023.","Gvoke prescriptions up 85% in Q4, retail share ~17%; Keveyis at high end of $38-40M guidance; Recorlev launched Feb 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-22-000033","json":"https://secwatch.observer/filing/0001867096-22-000033.json","markdown":"https://secwatch.observer/filing/0001867096-22-000033.md","text":"https://secwatch.observer/filing/0001867096-22-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000033/0001867096-22-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000033/xers-20220308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:09:06.841220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}